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Abstract
Background & Aims—Regular screening with colonoscopy lowers colorectal cancer incidence 
and mortality. We aimed to determine patterns of repeat and surveillance colonoscopy and identify 
factors associated with over- and underuse of colonoscopy.
Methods—We analyzed data from participants in a previous Veterans Health Administration 
(VHA) study who underwent outpatient colonoscopy at 25 VHA facilities between October 2007 
and September 2008 (n=1455). The proportion of patients who received a follow-up colonoscopy 
was calculated for 3 risk groups, defined based on the index colonoscopy: no adenoma, low-risk 
adenoma, or high-risk adenoma.
Results—Colonoscopy was overused (used more frequently than intervals recommended by 
guidelines) by 16% of patients with no adenomas, 26% with low-risk adenomas, and 29% with 
high-risk adenomas. Most patients with high-risk adenomas (54%) underwent colonoscopy after 
the recommended interval or did not undergo colonoscopy. Patients who received a follow-up 
recommendation that was discordant with guidelines were more likely to undergo colonoscopy too 
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early (no adenoma odds ratio [OR], 3.80; 95% CI, 2.31–6.25 and low-risk adenoma OR, 5.28; 
95% CI, 1.88–14.83). Receipt of colonoscopy at non-academic facilities was associated with 
overuse among patients without adenomas (OR, 5.26; 95% CI, 1.96–14.29) or with low-risk 
adenomas (OR, 3.45; 95% CI, 1.52–7.69). Performance of colonoscopies by general surgeons vs 
gastroenterologists (OR, 2.08; 95% CI, 1.02–4.23) and female sex of the patient (OR, 3.28; 95% 
CI, 1.06–10.16) were associated with overuse of colonoscopy for patients with low-risk adenomas. 
No factors examined were associated with underuse of colonoscopy among patients with high-risk 
adenomas.
Conclusions—In an analysis of patients in the VHA system, more than a quarter of patients 
with low-risk adenomas received a follow-up colonoscopies too early, whereas more than half of 
those with high-risk adenomas did not undergo surveillance colonoscopy as recommended. Our 
findings highlight the need for system-level improvements to facilitate the appropriate delivery of 
colonoscopy based on individual risk.
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Background
Colorectal cancer (CRC) screening is endorsed as an effective preventive service because it 
facilitates removal of adenomatous polyps and lowers CRC incidence and mortality.1 In 
contrast to other cancer screening tests (e.g., mammography, prostate-specific antigen 
testing), where there is controversy regarding if and when to screen, the value of CRC 
screening is widely recognized.2 Since the 1990s, both CRC incidence and mortality have 
declined,3 and a substantial proportion of this improvement has been attributed to regular 
screening.4 Cross-sectional data from both the National Health Interview Survey and 
Behavioral Risk Factor Surveillance System show an increase in overall screening use, from 
43% in 2000 to 65% in 2010.5–8 Most of the increase in CRC screening has been due to 
increased use of colonoscopy.9
Although a large research effort has focused on CRC screening initiation,10 relatively little 
attention has been paid to patterns of repeat screening and surveillance. Many patients who 
undergo screening colonoscopy have low- or high-risk adenomas that require removal and 
surveillance colonoscopy.11 Current guidelines12 recommend surveillance colonoscopy at 3 
years for high-risk adenomas (including size ≥10mm, high grade dysplasia, or ≥3 adenomas) 
and at 5–10 years for low-risk adenomas (1 or 2 adenomas each <10mm). For those with no 
or hyperplastic polyps, guidelines recommend continuing average-risk screening with the 
next colonoscopy in 10 years. Potential deviation from screening guidelines includes both 
over- and underuse of repeat colonoscopy. Overuse of colonoscopy is concerning because it 
can increase risk of adverse events (e.g., bleeding, perforation), increase healthcare costs, 
and reduce the capacity for appropriate colonoscopy in underscreened populations.13–17 
Underuse of surveillance colonoscopy for those at higher risk has only recently been 
recognized as a potential missed opportunity for CRC prevention.18–20
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The economic and healthcare burden of CRC screening and surveillance is considerable. A 
greater effort is needed to ensure colonoscopy services are delivered at the appropriate 
intervals and to eligible patients. This is especially important as recent changes in healthcare 
policy place a higher emphasis on the value of preventive services.21 The purpose of this 
study was to describe patterns of repeat screening and surveillance colonoscopy use in a 
population-based sample of veterans and to identify factors associated with over- and 
underuse of colonoscopy.
Methods
Patients and Procedures
Patients were identified from a larger study22 on physician adherence to repeat colonoscopy 
guidelines for screening and polyp surveillance in a sample of medical facilities in the 
Veterans Health Administration (VHA). Details of the study have been previously 
reported.25 Briefly, patients who underwent an outpatient screening colonoscopy between 
October 2007 and September 2008 were sampled from 25 medical facilities representative 
of the geographic distribution, academic affiliation, and complexity level (a VHA measure 
of facility resources and medical complexity of Veterans seen) of all eligible VHA facilities. 
Patients were sampled from strata of facility, race, and sex, with oversampling of women 
and minorities. All patients were age 50–64 years at the index colonoscopy and had no 
history of CRC, inflammatory bowel disease, or colonoscopy during the 10 years preceding 
the index screening. Patients with inadequate bowel preparation or piecemeal polyp 
resection were also excluded. Medical records were manually abstracted for pathology 
results of the index colonoscopy. Eligible patients (n=1,455) were classified into the 
following clinical risk groups: no polyps/normal tissue, hyperplastic polyps only, low-risk 
adenomas (1 or 2 adenomatous polyps each <10mm), and high-risk adenomas (including 3 
or more adenomatous polyps, any adenomatous polyp ≥10mm, or any adenomatous polyp 
with high grade dysplasia). Villous architecture was not included in the definition of high-
risk adenomas because patients underwent an index colonoscopy between 2007 and 2008, 
where the information and references included in the 2006 polyp guidelines were still 
relevant.11 Further, in our pilot work,22 we found the proportion of villous architecture was 
rarely included in pathology results.
Repeat colonoscopy recommendations, as documented by the treating endoscopist, were 
abstracted from patient medical records after pathology results from the index colonoscopy 
were recorded. VHA policy requires documentation of patient communication of pathology 
results within 14 days of the procedure; follow-up recommendations were included in a 
variety of locations, including the endoscopy report (if no tissue was removed), progress 
notes, patient follow-up letters, and addendums to the endoscopy report.22
To determine use of repeat colonoscopy after the index screening, the presence of a 
colonoscopy procedure code (Current Procedural Terminology© codes 44388, 44389, 
44390, 44391, 44392, 44393, 44394, 44395, 44396, 44397, 45355, 45378, 45379, 45380, 
45381, 45382, 45383, 45384, 45385, 45386, 45387, 45394, 45397, G0105, G0121; 
International Classification of Diseases, Ninth Edition codes V7641, V7650, V7651) from 
October 2008 through September 2014 was obtained from VHA administrative claims 
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databases. Algorithms using these codes have been shown to accurately capture utilization 
of colonoscopy in the VHA.23,24 Colonoscopy receipt allow was classified as early (i.e., 
overuse), on time/appropriate, or late (i.e., underuse). We included a 2-month grace period 
around guidelines intervals when classifying colonoscopy (e.g., 4 years and 10 months to 5 
years and 2 months instead of 5 years exactly) to allow for some flexibility in patient 
scheduling of follow-up exams. Among patients with no adenoma, early colonoscopy 
included any colonoscopy received during the study period (i.e., because the follow-up 
period was 6 years, a colonoscopy that occurred during the study period was before the 
recommended 10-year interval). In the low-risk adenoma group, early colonoscopy was 
defined as a colonoscopy within 4 years and 10 months of the index screening. On time 
colonoscopies included a colonoscopy received from 4 years and 10 months after the index 
screening through the end of the study period or no colonoscopy. For patients with high-risk 
adenomas, early colonoscopies were defined as a colonoscopy within 2 years and 10 months 
of the index screening. On time colonoscopies were considered those received from 2 years 
and 10 months to 4 years and 2 months after the index screening. A late colonoscopy was 
defined as a colonoscopy received later than 4 years and 2 months after the index screening 
or no colonoscopy.
Statistical Analysis
Descriptive statistics (frequencies, weighted proportions and means) were used to examine 
patient-, physician-, and system-level characteristics by clinical risk group. Proportions and 
means were estimated with stratum-specific sample weights to account for the complex 
survey design. Sample weights were calculated as the inverse of the sampling proportion for 
each sampling stratum. Standard errors were obtained using the Taylor linearization method 
for robust variance estimation of descriptive statistics and regression parameters.
Patient characteristics included sex (male vs. female), race/ethnicity (non-Hispanic white vs. 
other), age, and comorbidity. Comorbidity was scored using the Charlson comorbidity index 
with New Jersey Medicare Data weights.25,26 Physician characteristics included specialty 
(gastroenterology, general surgery, internal medicine, other) and repeat colonoscopy 
recommendation at the index screening (adherent vs. non-adherent). Follow-up 
recommendations were considered non-adherent if the recommendation was for any interval 
other than 10 years for no adenomas, less than 5 years or greater than 10 years for low risk 
adenomas, and other than 3 years for high risk adenomas. System-level characteristics 
included academic affiliation (academic vs. non-academic), facility complexity level (high 
vs. medium/low), and geographic region (Northeast, Midwest, South, West). Facility 
complexity level was determined by characteristics of the patient population, clinical 
services offered, education and research missions, and administrative complexity, as 
described in the 2012 VHA Facility Quality and Safety Report.27
Within each clinical risk group, we described characteristics of patients who underwent 
colonoscopy early (i.e., overuse), on time (i.e., guideline adherent), and late (i.e., underuse). 
We then used logistic regression models with stratum-specific sample weights to identify 
factors associated with underuse and overuse of repeat colonoscopy. Separate regression 
models were developed for the no adenoma (n=1,096), low-risk adenoma (n=231), and high-
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risk adenoma (n=128) groups. The no adenoma group combined patients with normal 
findings and hyperplastic polyps only on the index screening because the recommendation 
for repeat colonoscopy is the same for both risk groups. Overuse of colonoscopy was 
assessed as the dependent variable for the no adenoma and low-risk adenoma risk groups, 
and underuse was the dependent variable in the high-risk adenoma group. Associations 
between independent variables and colonoscopy overuse or underuse are reported as odds 
ratios (OR) and 95% confidence intervals (CI).
Secondary Analysis—To account for the possibility that colonoscopies may have been 
performed outside the VHA among Medicare-eligible patients, we conducted a secondary 
analysis that examined the proportion of patients who received a colonoscopy too early, on 
time, and too late in each clinical risk group by age. We compared colonoscopy use among 
patients tuning age 65 during the study period (i.e., were age 59–64 at the index 
colonoscopy) to those who remained younger than age 65 in all years of follow-up.
Statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC) and 
SUDAAN version 11.0 (Research Triangle Institute, Raleigh, NC).
Results
Characteristics of the study population by clinical risk group are shown in Table 1. No 
adenoma, low risk adenoma, and high risk adenoma groups were similar with respect to age 
and comorbidity score. The majority of patients were male, and a greater proportion of 
males and non-Hispanic whites had high or low risk adenomas compared to females or other 
racial/ethnic groups. A larger proportion of low-risk (54.8%) and high-risk (49.2%) 
adenoma patients received non-adherent recommendations for follow-up after the index 
colonoscopy than did patients without adenomas (31.8%).
No Adenoma
Among patients with no adenomas, 208 (16.4%) received a repeat colonoscopy too early, 
and 888 (83.6%) did not receive a colonoscopy during the study period and were considered 
guideline adherent (Table 2). Patients who received a non-adherent recommendation for 
follow-up at the index colonoscopy (OR 3.80, 95% CI 2.31–6.25) or were treated in a non-
academically affiliated facility (OR 5.26, 95% CI 1.96–14.29) had higher odds of receiving 
colonoscopy early (Table 3) compared to patients who received an adherent 
recommendation or were treated in an academically-affiliated facility.
Low-Risk Adenoma
Over one-quarter (26.4%) of low-risk adenoma patients received a follow-up colonoscopy 
less than five years after the index screening. The remaining proportion (73.6%) either 
received a follow-up colonoscopy more than five years after the index screening or did not 
receive a colonoscopy during the study period (Table 2). Patients who were female (OR 
2.08, 95% CI 1.02–4.23), received a non-adherent recommendation for follow-up at the 
index colonoscopy (OR 5.28, 95% CI 1.88–14.33), or were treated in a non-academically 
affiliated facility (OR 3.45, 95% CI 1.52–7.69) were more likely to receive a follow-up 
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colonoscopy too early (Table 4). General surgery (vs. gastroenterology) physician specialty 
(OR 3.28, 95% CI 1.06–10.16) was also associated with colonoscopy overuse in the low-risk 
adenoma group.
High-Risk Adenoma
Of patients with high-risk adenomas, the majority (54.1%) received a follow-up 
colonoscopy greater than three years after the index screening or did not receive a follow-up 
colonoscopy. Only 17.3% of patients received a colonoscopy on time, and 28.7% received a 
colonoscopy too early (Table 2). No variables were significantly associated with underuse of 
colonoscopy in logistic models comparing patients who received colonoscopy late to 
patients who underwent colonoscopy on time (Table 5). Similar results were observed when 
underuse was compared to appropriate use and overuse combined (results not shown).
Results of the secondary analysis that examined the proportion of patients who received a 
colonoscopy too early, on time, and too late in each clinical risk group by age are shown in 
Supplementary Table 1. In the high-risk adenoma group, colonoscopy underuse was higher 
in the Medicare-eligible subgroup (59.5%) compared to patients younger than age 65 
(47.5%), although the difference was not statistically significant (p=0.55). The proportion of 
patients who received a colonoscopy too early was similar among younger patients in both 
the no adenoma (age <65: 18.7% vs. age ≥65: 14.0%, p=0.12) and low-risk adenoma (age 
<65: 29.0% vs. age ≥65: 23.7%, p=0.55) groups.
Discussion
Our results suggest deviations from guideline recommendations for follow-up and 
surveillance colonoscopy include both under- and overuse of colonoscopy. For both the no 
adenoma and low-risk adenoma groups, patients who received a non-adherent 
recommendation for follow-up at the index screening were more likely to receive 
colonoscopy too early. Findings from our earlier study showed more than one-third of 
physicians recommend repeat colonoscopy be performed earlier than guidelines suggest.22 
Others similarly report only a minority of endoscopists give follow-up recommendations 
consistent with clinical guidelines,14,16,28 with many instead favoring shorter follow-up 
intervals. In a survey17 of a nationally representative sample of gastroenterologists and 
surgeons regarding their attitudes toward frequency of surveillance after polypectomy, 
physicians frequently recommended surveillance colonoscopy earlier than specified by 
guidelines. Other physician surveys29–31 show many endoscopists either lack knowledge 
regarding follow-up recommendations or disagree with guidelines. Most of these studies 
focus exclusively on recommendations and lack follow-up data on whether patients undergo 
repeat exams, which precludes the ability to examine the association between physician 
recommendation and colonoscopy receipt. Our study extends the findings of previous 
research by demonstrating that, not only do physicians consistently deviate from guidelines 
when making recommendations, but that those recommendations are the primary driver of 
undergoing colonoscopy. Targeting endoscopists’ recommendation for follow-up (e.g., by 
requiring clinical justification of intervals not aligned with guidelines) may be an effective 
strategy to improve appropriate receipt of colonoscopy.
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Overuse of colonoscopy in the no adenoma and low-risk adenoma groups was also 
associated with non-academically affiliated facilities. Non-adherent physician 
recommendations, patient age, and comorbidity were similar across academic and non-
academic facilities.22 A non-academic affiliation also does not imply lower patient volume, 
and there is no financial incentive for colonoscopy in any VHA facility, regardless of 
academic affiliation. Rather, there may be important differences in the organization and 
delivery of healthcare in non-academic settings that contribute to inappropriate use of 
colonoscopy. One possibility is that primary care providers in the community are more 
likely to manage specialty care and have responsibility for a broader range of services.32 In 
our study, gastroenterology was the predominant physician specialty in academic facilities 
(57%), whereas general surgery was more common in non-academic facilities (57%). This 
difference is also consistent with our finding that general surgery (vs. gastroenterology) was 
associated with colonoscopy overuse in the low-risk adenoma group. There are likely also 
differences in reminder and audit systems across academic and non-academic clinics in the 
VHA. Most VHA facilities have an average-risk CRC screening reminder, but only some 
have a colonoscopy reminder system for adenoma or cancer surveillance.
Although we observed some overuse of colonoscopy in normal and low-risk patients, a 
larger proportion of patients with high-risk adenomas did not receive follow-up colonoscopy 
at the recommended interval. More than half of patients with multiple or advanced 
adenomas either received surveillance colonoscopy too late or did not undergo colonoscopy 
up to six years after the index screening. Previous research19 of participants in the Prostate, 
Lung, Colorectal, and Ovarian (PLCO) cancer screening trial shows 27% of trial participants 
with advanced adenomas did not undergo surveillance colonoscopy within seven years. The 
higher prevalence of colonoscopy underuse (54%) in our study may be due to differences in 
the patient populations, where patient motivation to participate in clinical trials such as 
PLCO is likely to positively affect adherence. In addition, none of the explanatory variables 
in our study were associated with underuse of colonoscopy among higher risk patients. Non-
adherent physician recommendations for follow-up and treatment in non-academically 
affiliated clinics were associated with overuse only in the no and low-risk adenoma groups. 
There may be other reasons for underuse of surveillance colonoscopy among patients with 
high risk adenomas not captured in our data.
A limitation of the study is our inability to fully explain reasons for over- and underuse of 
colonoscopy during the study period that may be due to patient or physician preferences or 
inadequacies in the healthcare system. For example, the large number of patients with high-
risk adenomas who did not receive colonoscopy may be related to a lack of systematic 
monitoring of when repeat colonoscopy should be performed. Although scheduling and wait 
times may prohibit some patients from obtaining colonoscopy on time, our data showed only 
a 5% increase in colonoscopy use among high-risk adenoma patients in the three years after 
it was due. This is likely not a problem of access or delayed care (i.e., where more 
colonoscopies would be expected in years 4–6) but could indicate patients are not in contact 
with the healthcare system regarding follow-up. Another possibility is that patients who 
turned 65 during the follow-up period may have received a colonoscopy covered under 
Medicare outside the VHA. This limitation highlights the difficulty of accurately assessing 
the number of individuals receiving any colonoscopy across healthcare systems. However, 
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results of our sensitivity analysis suggest underuse was still high (48%) among younger 
patients with high-risk adenomas (i.e., those age 50–58 at the index colonoscopy who did 
not become eligible for Medicare), and only a minority (24%) were classified as on time. 
There were also some older patients who underwent colonoscopy on time or early, 
suggesting many dual-eligible patients continue to seek care related to polyp surveillance in 
the VHA. Better measurement of colonoscopy use, especially among patients who are dual-
eligible, may be facilitated by cross-talk of electronic health records between different 
healthcare systems. There may also be patient or physician preferences for early use of 
colonoscopy (e.g., patient symptoms) that account for some of the variation we observed in 
overuse. We were not able to distinguish between colonoscopies performed for diagnostic 
reasons and routine follow-up. Finally, characteristics of the VHA population (e.g., majority 
male, access to health benefits) may not be generalizable to other populations, and there may 
be different patterns of follow-up colonoscopy use in other clinical settings. Because there 
are no financial incentives to perform more frequent colonoscopies in the VHA, the results 
may underestimate the use of follow-up colonoscopy in systems where financial incentives 
influence colonoscopy performance.
Our study also has several strengths. Few studies have been able to examine appropriate 
receipt of surveillance colonoscopy because it requires long periods of observation in a 
relatively closed healthcare system. We used a complex sampling strategy to obtain a 
representative sample of patients seeking care in an integrated delivery system and had 
follow-up data after the index screening. In addition, because there is no method or 
algorithm to identify the presence of adenoma in administrative data, claims-based analyses 
have been limited in their ability to classify patients by clinical risk group. Polypectomy is 
often used as a proxy measure for adenoma removal,18 but this may not accurately capture 
the number of patients who are eligible for shorter follow-up intervals. We had detailed 
pathology reports at the index screening that allowed us to determine whether the timing of 
repeat colonoscopy was guideline-appropriate based on clinical risk. We also had 
information on physician recommendation for follow-up and were able to establish its 
importance in relation to receipt of colonoscopy. Although many studies report physicians 
frequently recommend follow-up intervals in excess of guidelines, the relevance of 
physician recommendation in predicting colonoscopy completion has not been extensively 
evaluated.
In summary, the results of this study paint a complex picture of colonoscopy overuse and 
underuse. Our findings highlight the need for system-level improvements that may facilitate 
appropriate delivery of repeat colonoscopy. Enhancing existing information systems to 
systematically track patients by clinical risk group could identify patients eligible for 
surveillance colonoscopy when testing is due. Reminder and recall systems can be set to 
guideline-recommended intervals that alert both physicians and patients to schedule 
colonoscopy. Other changes include computer prompts or lock-outs, which prohibit 
physicians from ordering inappropriate procedures without override. As healthcare reform 
continues to emphasize the value of preventive services, such as colonoscopy, these 
improvements are critical to maximizing the value and benefit of CRC surveillance 
strategies.
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